Laurie B. Keating

Laurie B. Keating

Imbria Pharmaceuticals, 2019 to 2020 Immuneering Corporation, 2021 Imago BioSciences, Inc., 2021 PepGen, Inc., 2022

Laurie is an enterprise wide, strategic leader with entrepreneurial insights and three decades of executive management, Board and Board counselling experience in diverse settings. She has expertise in M&A, business development, finance, governance, quality, government affairs, compliance, and human resources, in addition
to business law, intellectual property and litigation.

She served as the founding CEO of privately held Hydra Biosciences, and for six years on its Board of Directors. She is currently a director of Immuneering Corporation (Nasdaq: IMRX). She has also served for more than ten years on the Board of MassBIO. She is a former director of privately held Imbria Pharmaceuticals and the Boston Public Library Foundation and a past chair of BIO’s General Counsel Committee. She also served on the biopharmaceutical industry executive team appointed to negotiate a new five year Prescription Drug User Fee Agreement (PDUFA VI) with FDA leadership that was enacted into law in 2017.

Laurie was Executive Vice President, General Counsel and Corporate Secretary of Alnylam Pharmaceuticals Nasdaq: ALNY ), the leading RNAi therapeutics company, which she joined in 2014. She served on the executive team reporting to the CEO and led the global Public Policy/Government Relations , Legal, and Intellectual Property groups for this commercial stage $20B+ market cap company which gre w from ~300 to 1500+ employees worldwide during her seven year tenure. Alnylam launched three drugs in a little more than two years, including ONPATTRO, the first ever approved RNAi therapeutic. Laurie served as Secretary to
Alnylam’s Board, developing Board and Committee agendas with the Chairs and CEO and advising the Board on financings, strategic collaborations, governance, oversight of corporate strategy , enterprise and cyber security risks, and litigation (including multi country IP matters).

Prior to Alnylam, she served as SVP, General Counsel and Corporate Secretary of Millennium Pharmaceuticals, a commercial stage company, where she led the Legal, Intellectual Property, Quality and Compliance groups and reported to the CEO, making strategic contributions to transactions that broadened Millennium’s pipeline as well as to the competitive positioning and maintenance of exclusivity for Millennium’s primary product VELCADE. Millennium was acquired by Takeda Pharmaceuticals in 2008 at a 53% premium for $8.8B. In 2002, Laurie co founded Hydra, a venture backed research stage company, and served as founding CEO raising $10M in a Series A round with Polaris, Abingworth and NEA, concluding IP in licenses and pharma collaborations and hiring the team needed to build the company. She and the Hydra leadership team raised an additional $19M in a Series B round led by Lilly Ventures. Previously, she served as an executive at three high growth technology companies, including Sybase which went public and grew from approximately 400 to 6,000 employees worldwide during Laurie’s tenure. Based on her executive contributions and leadership of the global legal group at Sybase, she was named one of the 45 most influential in-house lawyers in the U.S. under age 45.

Laurie earned her bachelors degree in Economics from the University of California at Berkeley, and her JD from the University of California, Hastings College of the Law, where she graduated Order of the Coif.